Surge Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2021

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Founded in 2021 by Michael Goldberg (CEO), and based in Massachusetts, US, Surge Therapeutics is a biotechnology research platform that is developing a therapeutic medication that helps cancer patients to live longer lives by preventing post-surgical cancer recurrence. In July 2023, Surge raised USD 32 million in series B funding led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital Investments, 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango Venture Capital. The company provides the SURGERx platform, which is intended to increase the efficacy and safety of immunotherapy medication provided to cancer patients following tumor removal surgery. To improve patient survival results, the firm provides an injectable biodegradable hydrogel that allows for the extended, localized release of cancer immunotherapy at the site of surgical tumor removal.

Current Investors

Pitango Venture Capital, Khosla Ventures, Alumni Ventures Group

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy

Website

www.surgetx.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.